Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review

被引:3
作者
Buczynska, Angelika [1 ]
Kosciuszko, Maria [2 ]
Kretowski, Adam Jacek [1 ,2 ]
Poplawska-Kita, Anna [2 ]
机构
[1] Med Univ Bialystok, Clin Res Ctr, Bialystok, Poland
[2] Med Univ Bialystok, Dept Endocrinol Diabetol & Internal Med, Bialystok, Poland
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
papillary thyroid cancer; angioinvasion; VFGF; oxidative stress; integrins; sortilin; podoplanin; NADPH OXIDASE NOX4; GROWTH-FACTOR VEGF; OXIDATIVE STRESS; KINASE INHIBITORS; VASCULAR INVASION; PROGNOSTIC VALUE; DOUBLE-BLIND; CARCINOMA; SORTILIN; SURVIVAL;
D O I
10.3389/fendo.2023.1261860
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, and angioinvasion, the invasion of blood vessels by cancer cells, is a crucial pathological feature associated with disease progression and poor prognosis. Thus, a comprehensive search of scientific databases was conducted to identify relevant studies investigating angioinvasion markers in PTC. The selected studies were reviewed and analyzed to assess the clinical significance and potential utility of these markers in predicting angioinvasion and guiding treatment decisions. Numerous studies have investigated various markers associated with angioinvasion in PTC, including oxidative stress, vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and other angiogenic factors. The results indicate that increased expression of these markers is correlated with the presence and extent of angioinvasion in PTC. Moreover, some studies suggest that these markers can serve as prognostic indicators and guide therapeutic strategies, such as selecting patients for more aggressive treatment approaches or targeted therapies. The findings from the reviewed literature highlight the potential clinical utility of angioinvasion markers in PTC. The identification and validation of reliable markers can aid in assessing the risk of angioinvasion, predicting disease progression, and optimizing treatment decisions for patients with PTC. However, further research and validation on larger patient cohorts are necessary to establish the robustness and generalizability of these markers in clinical practice.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review
    Geropoulos, Georgios
    Psarras, Kyriakos
    Papaioannou, Maria
    Giannis, Dimitrios
    Meitanidou, Maria
    Kapriniotis, Konstantinos
    Symeonidis, Nikolaos
    Pavlidis, Efstathios T.
    Pavlidis, Theodoros E.
    Sapalidis, Konstantinos
    Ahmed, Nada Mabrouk
    Abdel-Aziz, Tarek Ezzat
    Eddama, Mohammad M. R.
    IN VIVO, 2022, 36 (04): : 1551 - 1569
  • [42] Unusual metastasis of papillary thyroid cancer to the pancreas, liver, and diaphragm: a case report with review of literature
    Haoyuan Ren
    Nengwen Ke
    Chunlu Tan
    Xing Wang
    Wen Cao
    Xubao Liu
    BMC Surgery, 20
  • [43] Biological markers with potential clinical value in endometrial cancer - review of the literature
    Taoussi, Nadia
    Alghamdi, Ali
    Futyma, Konrad
    Rechberger, Tomasz
    GINEKOLOGIA POLSKA, 2017, 88 (06) : 331 - 336
  • [44] Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells
    Yeo, Dannel
    Bastian, Althea
    Strauss, Heidi
    Saxena, Payal
    Grimison, Peter
    Rasko, John E. J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [45] Clinical behaviour of papillary thyroid cancer oncocytic variant: Stage-matched comparison versus classical and tall cell variant papillary thyroid cancer
    Okuyucu, K.
    Ince, S.
    Cinar, A.
    San, H.
    Samsum, M.
    Dizdar, N.
    Alagoz, E.
    Demirci, I.
    Ozkara, M.
    Gunalp, B.
    Karacalioglu, A. O.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (02): : 100 - 105
  • [46] The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage
    Beisa, Augustas
    Kvietkauskas, Mindaugas
    Beisa, Virgilijus
    Stoskus, Mindaugas
    Ostaneviciute, Elvyra
    Jasiunas, Eugenijus
    Griskevicius, Laimonas
    Strupas, Kestutis
    LANGENBECKS ARCHIVES OF SURGERY, 2017, 402 (02) : 227 - 234
  • [47] Predictive value of systemic inflammatory markers for recurrence of papillary thyroid cancer
    Wang, Guoqiang
    Ma, Yahui
    Liu, Yixiang
    Fan, Yuzhu
    Miao, Xiang
    Zhang, Yiqi
    Zhu, Hongbo
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (05) : 743 - 748
  • [48] Exploring the diagnosis markers for gallbladder cancer based on clinical data
    Zhang, Lingqiang
    Miao, Runchen
    Zhang, Xiude
    Chen, Wei
    Zhou, Yanyan
    Wang, Ruitao
    Zhang, Ruiyao
    Pang, Qing
    Xu, Xinsen
    Liu, Chang
    FRONTIERS OF MEDICINE, 2015, 9 (03) : 350 - 355
  • [49] Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients
    Liang, J.
    Zeng, W.
    Fang, F.
    Yu, T.
    Zhao, Y.
    Fan, X.
    Guo, N.
    Gao, X.
    ACTA OTORHINOLARYNGOLOGICA ITALICA, 2017, 37 (05) : 393 - 400
  • [50] Histological Variants of Papillary Thyroid Cancer in Relation to Clinical and Morphological Parameters and Prognosis
    Ivanov, A. A.
    Bakarev, M. A.
    Lushnikova, E. L.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 174 (05) : 647 - 652